2023 Archives | Therakos Healthcare Limited

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

By Emma2023, Press release

Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for...

June 13, 2023

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX^® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

By Emma2023, Press release

CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD DUBLIN – March 9, 2023 – Mallinckrodt plc, (NYSE American: MNK)(“Mallinckrodt” or...

March 9, 2023

Medical Affairs

News and Media

Careers

Integrity and Compliance

EU Privacy Notice

US Terms and Conditions

US Privacy Policy

Your California Privacy Rights

Purchase Order Terms and Conditions

UK Carbon Reduction Plan

Product Quality and Safety

2023

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

Therakos Healthcare Limited

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX^® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)